MA30707B1 - DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa. - Google Patents
DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa.Info
- Publication number
- MA30707B1 MA30707B1 MA31700A MA31700A MA30707B1 MA 30707 B1 MA30707 B1 MA 30707B1 MA 31700 A MA31700 A MA 31700A MA 31700 A MA31700 A MA 31700A MA 30707 B1 MA30707 B1 MA 30707B1
- Authority
- MA
- Morocco
- Prior art keywords
- coagulation factor
- isoserin
- inhibitors
- derivatives
- factor ixa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
- C07C1/26—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero-atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2529/00—Catalysts comprising molecular sieves
- C07C2529/04—Catalysts comprising molecular sieves having base-exchange properties, e.g. crystalline zeolites, pillared clays
- C07C2529/06—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof
- C07C2529/40—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
Abstract
L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) PRÉSENTANT UNE ACTIVITÉ ANTITHROMBOTIQUE, QUI INHIBENT EN PARTICULIER LE FACTEUR DE COAGULATION SANGUINE IXA. L'INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS PERMETTANT DE LES PRODUIRE ET LEUR UTILISATION COMME MÉDICAMENTS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006042926 | 2006-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30707B1 true MA30707B1 (fr) | 2009-09-01 |
Family
ID=38847022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31700A MA30707B1 (fr) | 2006-09-13 | 2009-03-06 | DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa. |
Country Status (22)
Country | Link |
---|---|
US (1) | US8097758B2 (fr) |
EP (1) | EP2069289B1 (fr) |
JP (1) | JP5249226B2 (fr) |
KR (1) | KR20090050081A (fr) |
CN (1) | CN101516834B (fr) |
AR (1) | AR063708A1 (fr) |
AU (1) | AU2007297013B2 (fr) |
BR (1) | BRPI0716991A2 (fr) |
CA (1) | CA2663544A1 (fr) |
CL (1) | CL2007002652A1 (fr) |
IL (1) | IL197504A (fr) |
MA (1) | MA30707B1 (fr) |
MX (1) | MX2009002047A (fr) |
MY (1) | MY150745A (fr) |
NO (1) | NO20091110L (fr) |
NZ (1) | NZ575603A (fr) |
RU (1) | RU2446157C2 (fr) |
SG (1) | SG174080A1 (fr) |
TW (1) | TWI394570B (fr) |
UY (1) | UY30585A1 (fr) |
WO (1) | WO2008031509A1 (fr) |
ZA (1) | ZA200900807B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003220222A1 (en) | 2002-03-13 | 2003-09-29 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
WO2006084033A1 (fr) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions et procedes pour l'amelioration de la fonction cognitive |
WO2008030118A1 (fr) * | 2006-09-07 | 2008-03-13 | Industrial Research Limited | Inhibiteurs amines acycliques de la 5'-méthylthioadénosine phosphorylase et nucléosidase |
EP2282735B1 (fr) | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Modulateurs du pp2a pour traiter alzheimer, parkinson, diabete |
US8642582B2 (en) | 2008-12-05 | 2014-02-04 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
EP2473491B1 (fr) * | 2009-08-31 | 2013-07-17 | Mochida Pharmaceutical Co., Ltd. | Composés morpholinones comme inhibiteurs du facteur ixa |
US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
CN109627218B (zh) * | 2018-11-27 | 2022-03-29 | 深圳市龙华区中心医院 | 一种抗凝小分子化合物及其应用和包含其的药物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4238260A1 (de) | 1992-11-12 | 1994-05-19 | Basf Ag | Substituierte ortho-Ethenylphenylessigsäurederivate |
EP0691976A1 (fr) | 1993-03-29 | 1996-01-17 | Queen's University At Kingston | Composes anticoagulants |
TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
US6107329A (en) * | 1995-06-06 | 2000-08-22 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
US6297269B1 (en) * | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
IL136954A0 (en) * | 1997-12-24 | 2001-06-14 | Aventis Pharma Gmbh | Indole derivatives as inhibitors of factor xa |
US6451832B2 (en) * | 1999-12-23 | 2002-09-17 | Boehringer Ingelheim Pharma Kg | Benzimidazoles with antithrombotic activity |
CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
JP4666440B2 (ja) * | 2000-06-30 | 2011-04-06 | 生化学工業株式会社 | アミノアルコール誘導体 |
US6642252B2 (en) | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
US7122559B2 (en) | 2003-02-11 | 2006-10-17 | Bristol-Myers Squibb Company | Phenylglycine derivatives useful as serine protease inhibitors |
US7056932B2 (en) * | 2003-12-19 | 2006-06-06 | Hoffman-La Roche Inc. | Heterocyclyl substituted 1-alkoxy acetic acid amides |
KR20080040027A (ko) * | 2005-09-02 | 2008-05-07 | 아스테라스 세이야쿠 가부시키가이샤 | Rock 억제제로서 아미드 유도체 |
WO2007029587A1 (fr) * | 2005-09-05 | 2007-03-15 | Dainippon Sumitomo Pharma Co., Ltd. | INHIBITEUR DE LA β-SECRÉTASE |
-
2007
- 2007-08-31 AU AU2007297013A patent/AU2007297013B2/en not_active Ceased
- 2007-08-31 CN CN2007800341822A patent/CN101516834B/zh not_active Expired - Fee Related
- 2007-08-31 JP JP2009527720A patent/JP5249226B2/ja not_active Expired - Fee Related
- 2007-08-31 EP EP07802031.0A patent/EP2069289B1/fr active Active
- 2007-08-31 KR KR1020097005160A patent/KR20090050081A/ko not_active Application Discontinuation
- 2007-08-31 BR BRPI0716991-4A2A patent/BRPI0716991A2/pt not_active IP Right Cessation
- 2007-08-31 SG SG2011058724A patent/SG174080A1/en unknown
- 2007-08-31 MY MYPI20090791 patent/MY150745A/en unknown
- 2007-08-31 MX MX2009002047A patent/MX2009002047A/es active IP Right Grant
- 2007-08-31 NZ NZ575603A patent/NZ575603A/en not_active IP Right Cessation
- 2007-08-31 RU RU2009113602/04A patent/RU2446157C2/ru not_active IP Right Cessation
- 2007-08-31 WO PCT/EP2007/007613 patent/WO2008031509A1/fr active Application Filing
- 2007-08-31 CA CA002663544A patent/CA2663544A1/fr not_active Abandoned
- 2007-09-11 AR ARP070104012A patent/AR063708A1/es not_active Application Discontinuation
- 2007-09-11 TW TW096133788A patent/TWI394570B/zh not_active IP Right Cessation
- 2007-09-11 UY UY30585A patent/UY30585A1/es not_active Application Discontinuation
- 2007-09-12 CL CL200702652A patent/CL2007002652A1/es unknown
-
2009
- 2009-02-03 ZA ZA200900807A patent/ZA200900807B/xx unknown
- 2009-03-06 MA MA31700A patent/MA30707B1/fr unknown
- 2009-03-09 IL IL197504A patent/IL197504A/en not_active IP Right Cessation
- 2009-03-09 US US12/400,189 patent/US8097758B2/en not_active Expired - Fee Related
- 2009-03-16 NO NO20091110A patent/NO20091110L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP5249226B2 (ja) | 2013-07-31 |
MX2009002047A (es) | 2009-03-06 |
US20090233949A1 (en) | 2009-09-17 |
SG174080A1 (en) | 2011-09-29 |
IL197504A0 (en) | 2009-12-24 |
MY150745A (en) | 2014-02-28 |
CN101516834B (zh) | 2013-04-03 |
KR20090050081A (ko) | 2009-05-19 |
EP2069289A1 (fr) | 2009-06-17 |
CN101516834A (zh) | 2009-08-26 |
TWI394570B (zh) | 2013-05-01 |
ZA200900807B (en) | 2009-11-25 |
IL197504A (en) | 2013-06-27 |
CL2007002652A1 (es) | 2008-02-08 |
AU2007297013B2 (en) | 2012-05-31 |
RU2009113602A (ru) | 2010-10-20 |
CA2663544A1 (fr) | 2008-03-20 |
US8097758B2 (en) | 2012-01-17 |
NZ575603A (en) | 2011-03-31 |
UY30585A1 (es) | 2008-05-02 |
JP2010503625A (ja) | 2010-02-04 |
AR063708A1 (es) | 2009-02-11 |
AU2007297013A1 (en) | 2008-03-20 |
WO2008031509A1 (fr) | 2008-03-20 |
EP2069289B1 (fr) | 2013-10-02 |
BRPI0716991A2 (pt) | 2013-10-08 |
NO20091110L (no) | 2009-06-09 |
RU2446157C2 (ru) | 2012-03-27 |
TW200829245A (en) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30707B1 (fr) | DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa. | |
EA200802213A1 (ru) | Способы лечения заболеваний крови | |
TW200510333A (en) | Benzimidazole compounds | |
TN2009000128A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
UA83875C2 (ru) | Производные хинолина для применения в качестве микобактериальных ингибиторов | |
MA33119B1 (fr) | Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase | |
MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
MY139942A (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
EA201070607A1 (ru) | Гербицидные соединения | |
TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
WO2006021884A3 (fr) | Composes d'aminoheteroaryle enantiomeriquement purs utilises comme inhibiteurs de proteine kinase | |
GEP20115171B (en) | Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor | |
MA32351B1 (fr) | Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer | |
NZ596583A (en) | Substituted dihydropyrazolones for treating cardiovascular and haematological diseases | |
TW200745004A (en) | Novel compounds, their preparation and use | |
HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
TW200638934A (en) | Heteroaryl compounds as P2Y1 receptor inhibitors | |
TW200509892A (en) | Novel aminobenzophenone compounds | |
IN2012DN00785A (fr) | ||
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
ATE432260T1 (de) | Pyridinderivate als pkc-theta-hemmer | |
MA31336B1 (fr) | Inhibiteurs de pi3k alpha a base de pyridopyrimidinone | |
WO2006023821A3 (fr) | Ligands pour aldocetoreductases | |
TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
MA30706B1 (fr) | Derives du tartrate destines a etre utilises comme inhibiteurs du facteur de coagulation ixa. |